Clinical trial
A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).
NCT02239211 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).
- Lead sponsor
- University of Birmingham
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 8, 2015
- Completion date
- October 23, 2018
- Enrollment
- 23 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
primary sclerosing cholangitis